The effect of antiresorptive therapy with nasal calcitonin (CT) in recently diagnosed hyperthyroid patients on conventional medical therapy as well as the evolution of bone metabolism were assessed. Forty-five patients with recent-onset hyperthyroidism (Ͻ12 weeks) were sex and menopause stratified and randomly allocated to treatment with carbimazole (Neotomizol), carbimazole plus low dose CT (Calsynar; 100 IU/day, 2 days/week), or carbimazole plus high dose CT (Calsynar; 100 IU/day, 14 days/month). Bone mineral density was measured by dual x-ray absorptiometry in lumbar spine, femoral neck, and Ward's triangle at 0, 9, and 18 months of treatment. We also determined free T 4 , free T 3 , TSH, osteocalcin, total and bone alkaline phosphatases, tartrate-resistant acid phosphatase, type I collagen C telopeptide, and urinary hydroxyproline every 3 months of follow-up.No significant difference was observed among treatments. A euthyroid state was attained at 3 months. Bone mass increased significantly at the 9 month evaluation (P Ͻ 0.05), with a 5-10% net gain during follow-up. Nevertheless, final bone mass was 4 -8% smaller than expected. Bone formation markers were increased at 0 and 3 months, with reductions at 6 -9 months; resorption bone markers showed a significant reduction at the 3 month evaluation.These results indicate that the euthyroid state partially reduces hyperthyroidism-associated osteopenia, with a bone mass recovery period during the 6 -9 early months of effective treatment. This recovery phase is characterized by raised bone formation markers and reduced bone resorption markers. The treatment with nasal CT at the doses assayed has no additional effect over that of attainment of the euthyroid state. (J Clin Endocrinol Metab 82: 1989, 1997 P REVIOUS hyperthyroidism is a risk factor for osteoporosis (1, 2), a major public health problem. In histomorphometric studies, reconstruction of the remodeling sequence in patients with hyperthyroidism discloses a marked shortening of both the resorptive and formative phases of the remodeling cycle, with a negative balance of 9 -10 m/remodeling cycle (3). Osteoclastic and osteoblastic activities are enhanced, with a predominance of bone resorption resulting in increased levels of bone turnover markers (4) and in decreased bone mass, as determined by single photon absorptiometry (5), dual photon absorptiometry (6), and dual x-ray absorptiometry (7,8), which is the most rapid, accurate, and reproducible method to evaluate bone mineral density (BMD) (9, 10).Serum bone alkaline phosphatase determined by immunoradiometric assay (IRMA) and serum type I collagen Cterminal telopeptide (ICTP) determined by RIA have been introduced recently as formation and resorption bone turnover markers, respectively (11). These precise bone markers could clarify, in a prospective study, the existence of a bone mass recovery period after attainment of euthyroidism that has been suggested in patients treated with radioiodine (12). Moreover, recent reports have suggested the revers...